Turn Therapeutics Inc.
TTRXNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | |
|---|---|---|
| Revenue | — | — |
| Operating income | −$5.9M | −$1.8M |
| Net income | −$3.2M | −$1.8M |
| Total assets | $12.2M | $2.0M |
| Total liabilities | $7.5M | $2.2M |
| Equity | $4.7M | −$177,432 |
| EPS (diluted) | $-0.12 | $-0.07 |
| Shares out. | 29.4M | 26.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −68.2%
- Return on assets
- −26.3%
- Return on capital (ROCE)
- −95.1%
- Liabilities / assets
- 61.5%
- Debt / equity
- 1.60×
- Book value / share
- $0.16
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -9.02distress
- Accruals / assets
- −5.2%clean
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 1 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Burnam Bradley EvanPassive (13G)Apr 6, 2026
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Burnam Bradley EvanOfficer — Chief Executive Officer | May 28, 2026 | Gift | 300,000 | $0.00 |
| Burnam Bradley EvanOfficer — Chief Executive Officer | Apr 2, 2026 | Gift | 300,000 | $0.00 |
| Chesed Abraham | Oct 23, 2025 | Buy | 14,286 | $4.60 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 64,613 | 2.8 | +25.7% |
| Apr 30, 2026 | 51,417 | 2.5 | -14.6% |
| Apr 15, 2026 | 60,219 | 1.7 | -4.6% |
| Mar 31, 2026 | 63,128 | 3.1 | -4.4% |
| Mar 13, 2026 | 66,046 | 3.4 | -6.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosureJun 1, 2026
- Regulation FD disclosureMay 27, 2026
- Regulation FD disclosureMay 19, 2026
- Regulation FD disclosureMay 18, 2026
- Results of operationsMay 11, 2026
- Results of operationsMar 31, 2026
- Entered a material agreement · New financial obligation · Unregistered equity sale · Regulation FD disclosureMar 24, 2026
- Regulation FD disclosureFeb 17, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4Jun 1, 2026
- 8-KCURRENT REPORTJun 1, 2026
- 8-KCURRENT REPORTMay 27, 2026
- 8-KCURRENT REPORTMay 19, 2026
- 8-KCURRENT REPORTMay 18, 2026
- C-TRMay 13, 2026
- 10-QQUARTERLY REPORTMay 11, 2026
- 8-KCURRENT REPORTMay 11, 2026
- SCHEDULE 13GApr 6, 2026
- 4Apr 3, 2026
- 4Apr 3, 2026
- 4Apr 3, 2026
- 4Apr 3, 2026
- EFFECTApr 2, 2026
- EFFECTApr 2, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.